News Release

MUSC Hollings Cancer Center researcher receives award to study pediatric brain cancer

Prestigious $300,000 Rally Foundation grant supports exploration of a subgroup of pediatric brain tumors that tend to be particularly deadly

Meeting Announcement

Medical University of South Carolina

Dr. Jezabel R. Blanco

image: Dr. Jezabel R. Blanco will use the Rally Foundation grant to further study a subgroup of pediatric brain tumors that tend to be particularly deadly. view more 

Credit: Medical University of South Carolina

In 2005, a 17-year-old boy named William was fighting a brain tumor for the second time in two years.

Rally Foundation founder and CEO Dean Crowe asked the teen's parents a simple question. "What can I do to help? And I will not make you dinner. This situation is so past dinner," he said.

William's mother, Nancy Olson, replied, "Raise money for childhood cancer research and fund the best research, wherever it may be."

Fast forward to 2020, and MUSC Hollings Cancer Center researcher Jezabel R. Blanco, Ph.D., pauses her research to take a Zoom call. She sees the faces of executives from the Rally Foundation and learns she has won a prestigious inaugural $300,000 research award. She is thrilled, as she is one of only two recipients in the country who will receive the Rally Career Development Award for Young Investigators.

What really gives her chills, though, is who else is on the call.

"The family of the child, the one who passed away from pediatric brain cancer and inspired the foundation to be created, was also on the call when I learned about winning this award," Blanco said. "It was breathtaking because this grant will fund research for the same type of tumor that took the life of their child."

It was a deeply felt moment for Crowe as well, who described how special it was when he saw the final scores for the inaugural Rally Career Development Award and realized that Blanco had won for her research on medulloblastoma.

"I felt like William was smiling down from heaven. It was very fitting. We are honored to be funding her cutting-edge research and believe that it will provide translational and clinical relevance for kids fighting medulloblastoma. We have high hopes for Dr. Blanco as an emerging thought leader in medulloblastoma."

Pediatric brain cancer

Blanco, who is originally from Spain, took a circuitous route to end up studying medulloblastoma, the most common of pediatric malignant brain tumors. It accounts for about 20% of all childhood brain tumors.

Blanco was studying Parkinson's disease as a graduate student at the University of Oviedo in Spain. Then she sought additional training in neurosciences at Columbia University in New York and became a postdoctoral fellow at the University of Miami in Florida, where she studied the role that pathways play in controlling embryonic development in cancer.

Through that research, she became interested in Sonic hedgehog signaling, a pathway not only implicated in controlling embryonic development but also in many cancer types, including brain tumors. As she began to explore more about the role of this signaling pathway in pediatric brain cancers, she realized she wanted to concentrate her efforts in this area and was drawn to the neuro-oncology program at MUSC Darby Children's Research Institute and Hollings Cancer Center. She came to MUSC in January as an assistant professor, studying pediatric brain tumors.

Blanco said she's grateful for the Rally Foundation grant. Each year in the United States, between 250 and 500 children are found to have medulloblastoma. Blanco hopes her research will lead to treatments that can save the lives of these children.

Survival rates in children with medulloblastoma depend on the patient's age and how much the tumor spreads, and children younger than the age of three often have lower survival rates because their disease tends to be more aggressive, she explained.

Although most children with medulloblastoma are cured of their disease, those tumors classified as the Sonic hedgehog subgroup harboring mutations in P53, a tumor suppressor gene, tend to be particularly deadly. This tumor is resistant to the current standard of care, and most of the treatments are in clinical trials. Blanco is particularly focused on targeting the stem cell reservoir of these tumors, as these cells are likely behind chemotherapy resistance and tumor relapse.

With this Rally Foundation grant, Blanco will further explore how the developmental pathway Sonic hedgehog gets activated in patients with mutations in the tumor suppressor P53 in medulloblastoma and further explore the drivers of the stem cells of these tumors. Her hope is that it might lead to targets for new drug treatments and be a catalyst for the development of new treatments for children diagnosed with this particular subtype.

Blanco said it is so meaningful to meet the families that are affected by this disease. This commits her even more strongly to her mission of helping children. "My focus is on saving kids. The word 'cancer' is always scary, but when talking about pediatric cancer, it is a different story. The way the families are affected by pediatric cancer leaves me wordless," she said.

Blanco explained that we need to find better treatments so that survival can go up to 100%.

"We also have to make sure new treatments are not going to be that harsh on them," she said. "We are working on that -- targeted therapeutics should be the future for pediatric cancer patients. If my research can help just one kid, then it will be worth it to me. If I am able to develop a drug that is able to make a difference for one kid and family, it will be worth it."


About MUSC

Founded in 1824 in Charleston, MUSC is the oldest medical school in the South, as well as the state's only integrated, academic health sciences center with a unique charge to serve the state through education, research and patient care. Each year, MUSC educates and trains more than 3,000 students and nearly 800 residents in six colleges: Dental Medicine, Graduate Studies, Health Professions, Medicine, Nursing and Pharmacy. The state's leader in obtaining biomedical research funds, in fiscal year 2019, MUSC set a new high, bringing in more than $284 million. For information on academic programs, visit

As the clinical health system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest quality patient care available, while training generations of competent, compassionate health care providers to serve the people of South Carolina and beyond. Comprising some 1,600 beds, more than 100 outreach sites, the MUSC College of Medicine, the physicians' practice plan, and nearly 275 telehealth locations, MUSC Health owns and operates eight hospitals situated in Charleston, Chester, Florence, Lancaster and Marion counties. In 2019, for the fifth consecutive year, U.S. News & World Report named MUSC Health the No. 1 hospital in South Carolina. To learn more about clinical patient services, visit

MUSC and its affiliates have collective annual budgets of $3.2 billion. The more than 17,000 MUSC team members include world-class faculty, physicians, specialty providers and scientists who deliver groundbreaking education, research, technology and patient care.

About MUSC Hollings Cancer Center

MUSC Hollings Cancer Center is a National Cancer Institute-designated cancer center and the largest academic-based cancer research program in South Carolina. The cancer center comprises more than 100 faculty cancer scientists and 20 academic departments. It has an annual research funding portfolio of more than $44 million and a dedication to reducing the cancer burden in South Carolina. Hollings offers state-of-the-art diagnostic capabilities, therapies and surgical techniques within multidisciplinary clinics that include surgeons, medical oncologists, radiation therapists, radiologists, pathologists, psychologists and other specialists equipped for the full range of cancer care, including more than 200 clinical trials. For more information, visit

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.